Brief Title
Factors Affecting Early Progress of Cochlear Implant Outcomes in Adults
Official Title
Barriers to Early Progress in Cochlear Implant Outcomes: a Non-interventional Feasibility Study
Brief Summary
The aim of this study is to understand how audiometric, cognitive and electrophysiological results relate to sentence recognition score in adults using currently a Nucleus cochlear implant.
Study Type
Observational
Primary Outcome
Score of the French MBAA2 sentence recognition test in quiet
Condition
Sensorineural Hearing Loss, Bilateral
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
30
Start Date
April 21, 2022
Completion Date
July 2022
Primary Completion Date
July 2022
Eligibility Criteria
Inclusion Criteria: - Adult subjects, 18 years or older - Subjects unilaterally implanted or bilaterally implanted with at least 6 months separating the two cochlear implantations. - Subjects who have been implanted between January 2016 and December 2021. - Subjects have received a Nucleus CI: CI512, CI522 or CI532 cochlear implants with non-rotating magnet, or CI600 series equivalent CI612, CI622 and CI632 with rotating magnet and external sound processors CP900 or CP1000 behind-the-ear, or Kanso or Kanso 2 off-the-ear types. - Subjects who are fluent in French (language used in the questionnaire and speech tests) - Subjects who are not opposed to participating in the study - Subjects for who the medical record data is available throughout the defined data search period. Exclusion Criteria: - Subjects with single-sided deafness (SSD). - Subjects who are not affiliated to the French Social Security. - Subjects who are under legal protection.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Mathieu Marx, MD, +33534638584, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT05265260
Organization ID
EMEA5798
Responsible Party
Sponsor
Study Sponsor
Cochlear
Collaborators
EVAMED
Study Sponsor
Mathieu Marx, MD, Principal Investigator, Hôpital Pierre-Paul Riquet
Verification Date
May 2022